ArticleJournal of the National Comprehensive Cancer Network : JNCCN2025
Management and Outcomes of Clostridioides difficile Infection in Patients on Immune Checkpoint Inhibitors.
Article in Journal of the National Comprehensive Cancer Network : JNCCN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundData on the severity, management, and outcomes of Clostridioides difficile infection (CDI) in patients presenting with diarrhea while receiving immune checkpoint inhibitors (ICIs) are limited. This study aimed to evaluate the course of CDI in this population and the overlapping diagnosis of immune-related enterocolitis (irEC).
methodsThis retrospective cohort included ICI-treated patients who presented with diarrhea and underwent CDI stool nucleic acid amplification PCR testing at Memorial Sloan Kettering Cancer Center between July 2015 and July 2021. Primary outcomes included CDI frequency, treatment regimens, and the need for immunosuppression for irEC.
resultsAmong 605 ICI-treated patients presenting with diarrhea, 111 (18%) tested positive for CDI. Of these, 84 (76%) were successfully treated with antibiotics alone, whereas 27 (24%) received additional immunosuppressive therapy for suspected or confirmed irEC. Compared with CDI-negative patients, those with CDI had higher rates of prior antibiotic exposure, abdominal pain, fever, bloody stools, and more severe diarrhea and colitis. However, they had lower rates of irEC requiring immunosuppression. Factors associated with the receipt of immunosuppression included CTLA-4-based immunotherapy and grade 3-4 diarrhea and colitis. The CDI recurrence rate was 20%, regardless of the treatment regimen used.
conclusionsIn the largest cohort to date of ICI-treated patients with diarrhea, CDI was identified in 18% of cases and was associated with prior antibiotic therapy. Most patients responded to antibiotics alone; however, 24% required immunosuppression for concurrent irEC, and 20% experienced CDI recurrence. Prompt CDI testing and thoughtful clinical treatment and monitoring may improve outcomes in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.